EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ EpCAM Antibody

Maasa Sasabe iD, Kenji Takashima, Shingo Sakashita iD, Yoshikatsu Koga iD, Takahiro Anzai, Shiqi Yang, Shinji Saijou, Akihiro Ishikawa, Toru Yamaguchi, Hideki Tanaka iD, Yusuke Yoda, Takeo Fujita und 3 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Maasa Sasabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Hauptthemen laut MEDLINE: Epithelial Cell Adhesion Molecule, Esophageal Neoplasms, Adenocarcinoma, Esophagogastric Junction. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Near‐infrared photoimmunotherapy (NIR‐PIT) is a tumor‐specific treatment using monoclonal antibody (mAb) photosensitizer conjugates, followed by near‐infrared light irradiation. This study aimed to identify the optimum target for treating esophagogastric junction (EGJ) adenocarcinoma and to evaluate the efficacy of NIR‐PIT using mAbs in preclinical models. Tumor samples from 46 consecutive patients who had undergone surgery without any prior treatment for EGJ adenocarcinoma were assessed for expression and homogeneity of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and epithelial cell adhesion molecule (EpCAM) through immunohistochemistry. Results showed positive rates of 22%, 13%, and 98% for EGFR, HER2, and EpCAM, respectively, with EpCAM also demonstrating the highest homogeneity (93%). Therefore, EpCAM was selected as the optimal target for NIR‐PIT. The fully human monoclonal antibody targeting EpCAM, adecatumumab, was conjugated with the photosensitizer IR700 at different dye‐antibody ratios (DAR2, DAR4, DAR7) and tested on OE19 cells and xenograft mouse models under near‐infrared light irradiation. NIR‐PIT with adecatumumab‐IR700 significantly reduced tumor size and improved prognoses compared to controls, with DAR2 showing the best balance of efficacy and minimal side effects. Notable EpCAM expression and homogeneity underpin EpCAM as a promising target for NIR‐PIT in EGJ adenocarcinoma. The fully human anti‐EpCAM antibody may be suitable for NIR‐PIT in EGJ adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial Cell Adhesion MoleculeEsophageal NeoplasmsAdenocarcinomaEsophagogastric JunctionImmunotherapyAntibodies, MonoclonalStomach NeoplasmsPhototherapyHumansAnimalsFemaleMiceMaleXenograft Model Antitumor AssaysMiddle AgedPhotosensitizing AgentsCell Line, TumorAgedErbB ReceptorsErb-b2 Receptor Tyrosine KinasesInfrared RaysMice, Inbred BALB C

Stichwörter der Autor:innen

epithelial cell adhesion moleculeesophagogastric junction adenocarcinomamonoclonal antibodynear‐infrared photoimmunotherapy (NIR‐PIT)photosensitizer IR700

Substanzen

Epithelial Cell Adhesion MoleculeAntibodies, MonoclonalPhotosensitizing AgentsErbB ReceptorsErb-b2 Receptor Tyrosine KinasesEPCAM protein, humanERBB2 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan.
  • Department of Gastroenterology and Endoscopy, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.
  • Division of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Department of Strategic Programs, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

ORCID-Profile: Maasa Sasabe, Shingo Sakashita, Yoshikatsu Koga, Hideki Tanaka, Shuichi Mitsunaga, Masahiro Yasunaga, Tomonori Yano

Förderung

  • National Cancer Center Research and Development Fund

Zitieren

APA

Sasabe, M., Takashima, K., Sakashita, S., Koga, Y., Anzai, T., Yang, S., Saijou, S., Ishikawa, A., Yamaguchi, T., Tanaka, H., Yoda, Y., Fujita, T., Mitsunaga, S., Yasunaga, M., & Yano, T. (2025). Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ EpCAM Antibody. Cancer Science. https://doi.org/10.1111/cas.70186

Vancouver

Sasabe M, Takashima K, Sakashita S, Koga Y, Anzai T, Yang S, et al. Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ EpCAM Antibody. Cancer Science. 2025. doi:10.1111/cas.70186

BibTeX
@article{Sasabe2025,
  author = {Sasabe, Maasa and Takashima, Kenji and Sakashita, Shingo and Koga, Yoshikatsu and Anzai, Takahiro and Yang, Shiqi and Saijou, Shinji and Ishikawa, Akihiro and Yamaguchi, Toru and Tanaka, Hideki and Yoda, Yusuke and Fujita, Takeo and Mitsunaga, Shuichi and Yasunaga, Masahiro and Yano, Tomonori},
  title = {Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ EpCAM Antibody},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70186}
}
Kostenlos starten →